Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Says Molecular Probes Acquisition to Close This Week

NEW YORK, Aug. 19 (GenomeWeb News) -Invitrogen said today it has received regulatory approval for its $325 million cash acquisition of Molecular Probes, and expects the acquisition to close this week.


The Carlsbad, Calif.-based company also said that it expects the acquisition to add to its earnings for 2003.


Invitrogen first announced the pending acquisition of privately-held Molecular Probes on July 2  The acquisition brings together Invitrogen, a genomic research reagents, software and service provider with the 28-year-old Eugene, Ore., provider of fluorescence-based technologies.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.